Why the study?
ARNIs reduce clinical events in HFrEF, but their use may be associated with adverse effects such as symptomatic hypotension.
What is the frequency of symptomatic hypotension in hospitalized adult patients with HFrEF treated with ARNIs?
What is the frequency of symptomatic hypotension in hospitalized adult patients with HFrEF treated with ARNIs?
Answers are grounded in this paper and cite their sources.
In a real-world cohort of hospitalized HFrEF patients, ARNI use was associated with a 25% rate of orthostatic hypotension, which is higher than reported in pivotal trials, emphasizing the need for careful monitoring.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Agudelo-Castañeda et al. (2025) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: